A Disease of Depth and Location
Crohn's disease is a chronic inflammatory bowel disease distinguished by two features that separate it from ulcerative colitis: it can affect any segment of the gastrointestinal tract (from mouth to anus, though the terminal ileum and colon are most common), and its inflammation extends through the full thickness of the bowel wall (transmural), not just the mucosal surface. This transmural nature is responsible for Crohn's unique complications — strictures, fistulae, and abscesses — that ulcerative colitis rarely produces.
Behaviour Classification
The Montreal classification categorises Crohn's disease by age at diagnosis, location, and behaviour. Behaviour is the most clinically significant dimension and evolves over time. Inflammatory (B1) disease — characterised by mucosal inflammation without complications — is the initial presentation in most patients. Over years, 50 to 70 percent progress to stricturing (B2) disease — where chronic inflammation produces fibrosis that narrows the bowel lumen — or penetrating (B3) disease — where transmural inflammation creates fistulae (abnormal connections between bowel and skin, bladder, vagina, or other bowel loops) or abscesses. Perianal disease (fistulae around the anus) affects approximately 30 percent of Crohn's patients.
Subclinical Progression
One of the most important — and most underappreciated — aspects of Crohn's disease is that structural damage can accumulate silently. Patients may feel well while subclinical inflammation quietly drives fibrosis and stricture formation. By the time symptoms recur, irreversible structural damage may have occurred. This concept — the disconnect between symptoms and disease progression — underpins the modern treat-to-target approach.
Treat-to-Target
Contemporary Crohn's management aims not just for symptom control (clinical remission) but for objective targets: endoscopic mucosal healing, normalisation of biomarkers (fecal calprotectin less than 150 micrograms per gram, normalisation of CRP), and ideally histological remission. Serial monitoring with biomarkers and interval endoscopy allows early detection of subclinical inflammation and pre-emptive treatment escalation — preventing the progression from inflammatory to stricturing or penetrating disease.
Therapeutic Landscape
Treatment options range from 5-aminosalicylates (limited efficacy in Crohn's, unlike UC), corticosteroids (for acute flares, not maintenance), immunomodulators (azathioprine, methotrexate), biologics (anti-TNF agents, anti-integrins, anti-IL-12/23 agents), and small molecules (JAK inhibitors, S1P receptor modulators). The choice depends on disease location, severity, behaviour, and patient factors. Surgery is not failure — up to 50 percent of Crohn's patients require at least one surgical procedure during their lifetime, and timely surgery for complications (strictures, abscesses, refractory fistulae) improves quality of life.
Patient Empowerment
Understanding that feeling well does not always equal being well is empowering, not alarming. It means that regular monitoring — even during remission — is protective, not excessive. Patients who engage actively with monitoring schedules, understand their biomarker trends, and maintain open communication with their gastroenterologist achieve better long-term outcomes.